SURVIVEDtoceranib × VEGFR2

Toceranib (VEGFR2/KDR inhibitor) for angiogenesis-driven hemangiosarcoma

What we’re testing

target · KDRVEGFR2 expressiontumor angiogenesis

Where it stands — still standing

Survived every test the engine could run. Nothing here is proven — that's the point.

Status on the engine: evidence supported · validation-ready. Nothing here is promoted automatically — a human holds the final call.

Follow the trail

See the evidence →2 tests

the pre-registered tests, verdict, and signed provenance

View the run →

the campaign that tested this idea — Falsification campaign — 45 candidate(s), runner=modal

Grounded in

PMID:19365060GSE95183

How we know it’s real

content-addressed · 92edb7070bc9da13…updated 2026-07-07

Every idea and every result is hashed so anyone can re-derive it. Want a drug or target put to the test? Suggest one →

Contribute to this idea

Have evidence, a critique, a replication, or compute to add? When contributor check-in is open you can submit a bounded packet — queued for human review, and it never changes the record on its own.

Checking whether check-in is open…